


January 27-29, 2026 | Boston, MA

www.molecular-glue-summit.com

SAVE \$900 BY
REGISTERING
BEFORE FRIDAY,
OCTOBER 31



4th Annual

Molecular Glue Drug Development Summit

Accelerating the Discovery of Molecular Glues Against Novel Undruggable Targets

Enabling Rapid Target Selection, Discovery & Rational Design of Degrading & Non-Degrading Molecular Glues to Develop Potent, Selective & Safer Cures for Cancer & Beyond

Your Expert Speakers Include:



Laura Silvan
Senior Director
Biogen



Anita Bellail
Chief Executive
Officer
HB Therapeutics



Kyle Eastman
Vice President, Head
of Chemistry
Halda Therapeutics



Jonathan Soloman
Director
Novartis



Goutham Narla
Chief Scientific
Officer
Rappta Therapeutics



Ingrid Wertz
Chief Executive
Officer
**Lyterian
Therapeutics**

These meetings offer an opportunity to hear about a wide variety of strategies being employed to identify molecular glues and to connect with individuals who are bringing a high level of innovative problem solving to these challenges **Past Speaker, Senior Director, Triana Biomedicines**

+1 617 455 4188 @ info@hansonwade.com

www.molecular-glue-summit.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Get Stuck into the 4th Molecular Glue Drug Development Summit



January 27-29, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

This year, continued investment and excitement has positioned molecular glues as a front runner in the race to drug the undruggable. **Magnet Bio** struck a \$1.2 billion deal with **Eli Lilly**, **Kymera Therapeutics** and **Gilead Sciences** entered a \$750 million partnership, and **Orionis Biosciences** announced a \$105 million collaboration with **Genentech**.

Yet, key challenges remain before we can fully realize glues' potential; namely selecting **targets amenable to glues**, the need for **highly sensitive assays** to detect weak interactions, and enabling **rational design**. Moreover, the industry is only beginning to explore the potential of **non-degrading molecular glues** and glue **applications beyond oncology**.

The **4th Molecular Glue Drug Development Summit** returns as the industry's only dedicated forum, exclusively enabling experts to overcome specific bottlenecks in glue discovery. This is your opportunity to hear the latest data and gain fresh insight into the discovery of novel molecular glues to kick-start and/or optimize your own pipelines.

Explore cutting-edge content spanning target selection principles, rational design frameworks, sensitive assay technologies, and ligand-first vs. biology-first strategies to enable rapid and reliable glue discovery. Delve into emerging frontiers in non-degrading molecular glues and approaches outside oncology to unlock new therapeutic modalities, expand glues to novel indications, and stay **ahead of the curve in the glues space**.

Join 70+ molecular glue experts working at the cutting edge of **Discovery Biology**, **Structural** and **Chemical Biology**, **Proteomics**, and **Medicinal Chemistry** to build the connections and scientific firepower you need to accelerate the development of safer, more selective molecular glues and leave equipped with actionable strategies to develop and progress rationally designed molecular glues toward the clinic.

What to Expect in 2026



70+
Attendees



22+
Expert
Speakers



7+
Networking
Hours



2
Interactive
Workshops




1
Scientific
Poster Session

4 Key Benefits of Attending:



Broaden the therapeutic horizon of molecular glues beyond oncology by exploring how **AevisBio**, **Degrome Therapeutics**, and **Hinova Pharmaceuticals** are advancing novel approaches in neurodegeneration and autoimmune disease - demonstrating dual mechanisms of action, translation from *in vitro* to *in vivo* models, and the potential to **deliver first-in-class therapies across areas of high unmet medical need**



Expand the frontier of molecular glue discovery by leveraging novel **E3 ligases** for greater diversity, specificity, and therapeutic potential. Gain insights into screening-first strategies, positive-selection systems, and large-scale library screens. Explore oncology and non-oncology programs advancing degraders, PPI modulators, and non-degraders with perspectives from **HB Therapeutics**, **Stanford University**, and the **Structural Genomics Consortium**



Unlock the therapeutic potential of molecular glues beyond degradation by exploring innovative mechanisms that stabilize, activate, or modulate protein function, **enabling access to previously undruggable targets** across oncology, neurodegeneration, and autoimmune disease, with insights from **Rappta Therapeutics**, **Rapafusyn Pharmaceuticals** and **Massachusetts General Hospital**



Accelerate molecular glue discovery through **cutting-edge technologies** by learning how advanced screening cascades, synthetic selection platforms, and AI-driven design can capture and prioritize early hits, unlock cooperative activity without structural data, and optimize ternary complex formation with insights from **Triana Biomedicines**, **Coltac Therapeutics**, **Parabilis Medicines**, and **Ternary Therapeutics**

What's New for Glues in 2026?



January 27-29, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

You Asked, We Listened! Explore Content Spanning:



E3 Ligases Beyond Cereblon



Early Glue Discovery



Non-Degrading Glues



Therapeutic Opportunities Beyond Oncology

Top Sessions:



Discovery of SW-3431, a First-in-Class Molecular Glue Activator with Potent & Selective Anti-Tumor Activity in PPP2R1A Mutant Cancers

Goutham Narla, Chief Scientific Officer, Rappta Therapeutics

1



Redefining Parkinson's Treatment with Dual-Action Molecular Glues

Dong Seok Kim, Chief Executive Officer, AegisBio

2



Harnessing Novel E3 Ligases to Unlock New Opportunities in Molecular Glue Drug Discovery

Dalia Barsyte-Lovejoy, Principal Investigator, Structural Genomics Consortium

3



12+

Companies Unveiling Never-Seen-Before Data



7+

Presentations on Non-Oncology & Non-Degrading Molecular Glues



7+

C-Level Speakers

New Companies for 2026 Include:



3

+1 617 455 4188 @ info@hansonwade.com

www.molecular-glue-summit.com



Your Expert Speakers

Pharma Powerhouses



Jonathan Soloman
Director
Novartis



Eugene Chekler
Senior Director
Takeda Pharmaceuticals



Milad Rouhimoghadam
Senior Scientist
AbbVie



Laura Silvian
Senior Director
Biogen

Biotech Trailblazers



Dong Seok Ki
Chief Executive Officer
AevisBio



Vivek Vishnudas
Chief Technology Officer &
R&D Site Head
BPGBio



Orli Even-Or
Director of R&D
Coltac Therapeutics



Chunhai Charlie Hao
Co-Founder
Degrome Therapeutics



Kyle Eastman
Vice President & Head of
Chemistry
Halda Therapeutics



Anita Bellail
Chief Executive Director
HB Therapeutics



Wu Du
Senior Vice President of
Medicinal Chemistry
Hinova



Ingrid Wertz
Chief Executive Officer
Lyterian Therapeutics



John McGee
Senior Vice President of
Platform Technology
Parabilis Medicines



Peggy Thompson
Vice President & Head of
Biology
Plexium



Rick Ewing
Vice President & Head of
Chemistry
Rapafusyn
Pharmaceuticals



Goutham Narla
Chief Scientific Officer
RAPPTA Therapeutics



Chris Tame
Chief Executive Officer
Ternary Therapeutics



Patrick Arsenault
Senior Director, Lead
Discovery
Triana Biomedicines

Distinguished Researchers



Mikolaj Slabicki
Principal Investigator
Massachusetts General
Hospital



Stephen Hinshaw
Senior Scientist
Stanford University



Gisele Nishiguchi
Targeted Protein
Degradation Center
Leader
St Jude Children's
Research Hospital



Dalia Barsyte-Lovejoy
Principal Investigator
Structural Genomics
Consortium

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Pre-Conference Workshop Day

Tuesday, January 27, 2026

Registration & Morning Coffee

8.30

Workshop A

9.00 - 12.00

Transforming Serendipity into Strategy through Rational Molecular Glue Design to Expand the Druggable Frontier

Rational design of molecular glues is more complex than traditional drug discovery, requiring stabilization of ternary complexes where binary binding can be weak. Limited structural data and current AI tools constrain predictive power, so most glues are still discovered empirically through cereblon-based libraries. This workshop will explore strategies to overcome these challenges, integrating computational predictions with experimental validation, improving ternary complex modelling, and expanding discovery beyond known E3 ligases.

Join this session to:

- Navigate the three-body problem and data gaps by leveraging ternary complex stabilization highlights the complexity of rational glue design and enables the identification of truly predictive design principles
- Overcome computational and AI limitations by applying advanced modeling to ternary complex energetics and cooperativity allows researchers to prioritize compounds more efficiently and reduce wasted experimental effort
- Transform screening versus rational design by shifting from empirical approaches toward predictive platforms unlocks the potential to explore new E3 ligases and expand chemical space, accelerating the discovery of first-in-class molecular glues

This workshop is perfect for teams seeking practical insights into overcoming data gaps, optimizing ternary complexes, and expanding their experimental toolkit for novel molecular glues.

Workshop Leader



Laura Silvian
Senior Director
Biogen

Lunch Break & Networking

12.00

Workshop B

1.00 - 4.00

Accelerating Molecular Glue Discovery: Capture & Prioritize Early Hits with Screening Cascades to Advance Effective Leads

Identifying early molecular glue hits requires sensitive assays, as standard binding or inhibition tests often fail to capture functional activity. Capturing hits requires carefully designed biochemical, cell-based, and proteomics assays that reflect ternary complex formation and target degradation. While ternary complexes remain central to glue discovery, recent insights suggest that maximal stability is not always optimal for degradation. This workshop will explore strategies for implementing tiered screening cascades, validating hits across multiple contexts, and considering target expression, E3 ligase availability, and multi-protein complexes to improve translation into downstream studies.

This workshop will gather experts to discuss:

- Capturing relevant hits using biochemical, cell-based, and proteomics assays detects transient PPIs and ternary complexes effectively
- Prioritizing meaningful candidates with tiered screening cascades to confirm degradation, selectivity, and mechanism while reducing false positives
- Accounting for biological context by considering target expression, E3 ligase availability, and multi-protein complexes and the dynamic nature of ternary interactions to improve translation *in vivo*

This session is designed for chemists, biologists, and translational scientists looking to optimize screening cascades and improve the reliability of early-stage hit selection.

Workshop Leaders



Patrick Arsenault
Senior Director,
Lead Discovery
Triana
Biomedicines



Stephen Hinshaw
Senior Scientist
Stanford
University



Gisele Nishiguichi
Targeted Protein
Degradation Center
Leader
St Jude Children's
Research Hospital

End of Pre-Conference Workshop Day

4.00

Conference Day One

Wednesday, January 28, 2026



8.00 Check-In & Light Breakfast



Eugene Chekler
Senior Director
Takeda
Pharmaceuticals

8.45 Chair's Opening Remarks

Developing Novel Molecular Glues Beyond Degradation Through Screening & Pharmacology Studies to Unlock Uncharted Therapeutic Pathways



Goutham Narla
Chief Scientific Officer
RAPPTA Therapeutics
NEW DATA
NEW COMPANY

9.00 **Discovery of SW-3431, a First-in-Class Molecular Glue Activator with Potent & Selective Anti-Tumor Activity in PPP2R1A Mutant Cancers**

- Targeting a tumor suppressor with small molecule glues to reactivate PP2A in cancer
- Mechanistic and structural insights into PP2A holoenzyme stabilization and downstream signaling effects
- Translational potential and development challenges, including chemistry optimization and preclinical efficacy



Rick Ewing
Vice President & Head
of Chemistry
Rapafusyn
Pharmaceuticals
NEW DATA

9.30 **RapaGlue™ Platform – A Novel Non-Degrading Molecular Glue Modality for Unlocking the Hard to Drug Proteome**

- Discover how RapaGlues™, a novel class of non-degrading macrocyclic peptide molecular glues, achieve potent, selective target engagement with long residence times, aided by AI/ML-driven design and structural insights
- Learn from case studies using DEL screening and X-ray crystallography that reveal unique binding modes, cryptic pocket engagement, and successful inhibition of challenging targets including transcription factors, SLCs, and TNF-alpha pathway proteins
- Explore strategies to optimize permeability, stability, and oral bioavailability of macrocyclic glues, expanding drug discovery opportunities across diverse and hard-to-drug protein classes



Mikolaj Slabicki
Principal Investigator
Massachusetts
General Hospital
NEW COMPANY

10.00 **Drug-Induced Polymerization as a Novel Mechanism for Target Modulation & Therapeutic Control**

- Exploring how small molecules such as BI-3802 induce BCL6 polymerization, leading to target sequestration and subsequent proteasomal degradation
- Harnessing chemically controlled on/off oligomerization switches for synthetic biology applications
- BTB-domain polymerization represents a broader mechanism across ZBTB transcription factors, enhancing chromatin occupancy and gene repression



10.30 **Morning Break & Speed Networking**

Join our speed networking session tailored for Molecular Glue professionals, like yourself, to connect with fellow industry peers to facilitate rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections within the space.

Driving Lead Optimization to Maximize Target Engagement & Translational Success



Jonathan Soloman
Director
Novartis
NEW DATA

11.30 **Beyond the Beta Turn: A Novel Structural Motif Bound by a CRBN Glue Degradator**

- A screen identified CRBN glues for TBK1
- Structure of the ternary CRBN-glue-TBK1 complex reveals a unique binding mode
- These TBK1 glues are selective over the closely related IKKe kinase



Ingrid Wertz
Chief Executive Officer
Lyterian Therapeutics
NEW DATA

12.00 **Co-Opting the Ubiquitin System for Therapeutic Benefit**

- Reviewing rational drug design strategies for molecular glues
- Comparing and contrasting different molecular glue systems
- Investigating more streamlined and complementary strategies to evaluate optimized compounds

Conference Day One

Wednesday, January 28, 2026



12.30 Lunch Break & Networking



Peggy Thompson
Vice President & Head
of Biology
Plexium

NEW DATA

1.30 From Screening to Pharmacology: Lead Optimization of a CDK2 Molecular Glue Degradator

- Mapping the journey from screening to hit identification for a CDK2 molecular glue degrader
- Defining and monitoring critical parameters during lead optimization to ensure biological relevance
- Translating early activity into downstream pharmacology to achieve the desired therapeutic profile

Expanding the Molecular Glue Universe to Unlock Therapeutic Opportunities Beyond Oncology Targets



Dong Seok Ki
Chief Executive Officer
AevisBio

NEW DATA

2.00 Redefining Parkinson's Treatment with Dual-Action Molecular Glues

- Dual actions on key pathogenic drivers – simultaneously degrading ZFP91 to suppress inflammation and blocking alpha-synuclein aggregation
- From neuroprotection to functional recovery – demonstrated broad beneficial effects in cognition and motor outcomes
- Validated across multiple models of neurodegeneration – robust and reproducible biological actions confirmed *in vitro* and *in vivo*



2.30 Afternoon Break & Poster Presentation Session

Take this opportunity to showcase your latest research and innovations with your peers and understand the strategies of your fellow Molecular Glue experts. Visit the website for the full T&Cs of submitting a poster



Chunhai Charlie Hao
Co-Founder
Degrome Therapeutics

NEW DATA

NEW COMPANY

3.30 Molecular Glue Degradators Promote Lysosomal Degradation of APP as a Therapeutic Strategy for Alzheimer's Disease

- Enhancing targeted degradation of amyloid precursor protein (APP) by leveraging CAPRIN1-dependent lysosomal pathways to advance therapeutic strategies for Alzheimer's disease
- Restoring neuronal stability through selective molecular glue modulation of APP processing, reducing amyloid accumulation and neurotoxicity
- Accelerating translational drug development using AI-assisted ligand and structure-based design to create blood-brain barrier-permeable APP degradators for Alzheimer's therapy



Wu Du
Senior Vice President
of Medicinal Chemistry
Hinova

NEW DATA

NEW COMPANY

4.00 Discovery of Novel VAV1 Molecular Glue Degradator with Superior Potency & Efficacy

- VAV1 is an emerging first in class target for a broad range of autoimmune and inflammatory diseases
- Discovery a class of orally available VAV1 degrader with a novel scaffold
- Lead compound demonstrates superior VAV1 degradation activity *in vitro* and superior efficacy *in vivo*



Eugene Chekler
Senior Director
Takeda Pharmaceuticals

4.30 Chair's Closing Remarks

4.45 End of Conference Day One

Conference Day Two

Thursday January 29, 2026



8.00 Check-In & Light Breakfast



Rick Ewing
Vice President & Head
of Chemistry
Rapafusyn
Pharmaceuticals

8.45 Chair's Opening Remarks

Harnessing Novel E3 Ligases for Molecular Glue Programs: Revealing New Targets & Accelerating Translation



Anita Bellail
Chief Executive
Director
HB Therapeutics
NEW DATA

9.00 **Harnessing Novel Molecular Glue Degradors to Target K-Ras Mutants & Overcome Resistance Pathways**

- Engaging a novel ligase for targeted degradation to selectively degrade mutant K-Ras while sparing the wild-type protein
- Dual-target effect via co-degradation of Seraph, addressing the major resistance pathway in K-Ras-driven cancers and creating a unique therapeutic opportunity
- Structural insights into ternary complex formation, revealing how the molecular glue stabilizes interactions between the ligase and target proteins, guiding next-generation degrader design



Stephen Hinshaw
Senior Scientist
Stanford University
NEW DATA
NEW COMPANY

9.30 **Expanding the Molecular Glue Toolbox: Harnessing Novel E3 Ligases**

- Explore innovative strategies to harness non-Cullin-based degradation mechanisms for targeted protein degradation
- Leverage structural insights to improve prediction accuracy and guide rational discovery of novel ligase-glue pairs
- Understand how bold discovery strategies and broader search spaces can accelerate breakthroughs in molecular glue therapeutics



Dalia Barsyte-Lovejoy
Principal Investigator
Structural Genomics Consortium

10.00 **Harnessing Novel E3 Ligases to Unlock New Opportunities in Molecular Glue Drug Discovery**

- Leveraging a large portfolio of novel E3 ligases in diverse screening campaigns (traditional screening, DEL, ML-based approaches, and ASMS) to expand the landscape of glue discovery
- Identifying hits that engage substrate recognition components of E3 ligases, supported by structural insights and mechanistic validation
- Highlighting case studies, including FBXO22 and a deubiquitinase-E3 ligase axis, as emerging examples of potential molecular glue mechanisms with translational relevance



10.30 Morning Break & Networking

Supercharging Molecular Glue Discovery with High-Sensitivity Assays, Tailored Libraries & Integrated PPI Technologies to Strengthen Hit Detection & Guide Lead Advancement



Orli Even-Or
Director of R&D
Coltac Therapeutics
NEW DATA
NEW COMPANY

11.30 **Advancing Molecular Glue Discovery through a Positive-Signal Bacterial Screening Platform**

- Combining in-silico with the power of our bacteria-based, synthetic positive selection screening system for new molecular glues
- Program insights covering oncology and non-oncology programs, with focus on ligase diversity, target specificity, and optimization process
- Future directions that include expanding beyond degraders to explore non-degraders and PPI modulators, supporting both scientific advancement and company growth strategy

Conference Day Two

Thursday January 29, 2026



John McGee
Senior Vice President
of Platform Technology
Parabilis Medicines
NEW DATA

12.00 A Screening-First Approach to Molecular Glue Discovery: Unlocking Cooperativity Without Structural Data

- Unlocking glue discovery without relying on structural information, opening new possibilities for difficult targets
- Leveraging two tandem 100M+ member library screens to move from initial binders to true cooperative molecular glues
- Ensuring conditional, cooperative activity that reduces off-target risks and enables safer non-degradation strategies



Chris Tame
Chief Executive Officer
Ternary Therapeutics
NEW DATA
NEW COMPANY

12.30 Accurate Prediction of Tractable Ternary Complexes & Optimised Molecular Glues for Any Protein-Protein Interaction

- An overview of Ternary's end-to-end molecular glue design platform
- Revealing *in vitro* validation of the platform
- Exploring current limitations to AI-enabled molecular glue design



1.00 Lunch Break & Networking



Vivek Vishnudas
Chief Technology
Officer & R&D Site
Head
BPGBio
NEW DATA

2.00 Biology-First Discovery of Non-Degrading Molecular Glues Targeting E2 Enzymes for Neurodegeneration

- Leveraging AI-driven biology discovery to identify ubiquitin-conjugating enzymes (E2s) as novel therapeutic target
- Demonstrating a unique mechanism of action by locking ubiquitin to E2 enzymes, preventing discharge, inhibiting enzyme function, and triggering autophagy to clear mutant huntingtin
- Advancing lead optimization efforts with the goal of progressing to animal proof-of-concept studies for neurodegenerative proteinopathies



Milad Rouhimoghadam
Senior Scientist
AbbVie
NEW DATA
NEW COMPANY

2.30 Platform for the Discovery of Molecular Glues

- Lighting up molecular glue biology in real time – we developed a NanoBRET-powered high-throughput platform that directly visualizes E3 ligase–substrate interactions in live cells, transforming molecular glue discovery from serendipity to systematic science
- From mechanism to molecules – by capturing dynamic CRBN–CUL4A and DCAF15–CUL4A assemblies with sensitive NanoBRET proximity assays, this platform delivers both mechanistic insight and a scalable engine to uncover new degraders across the CRL family
- Expanding the degradable proteome – applying this approach, we identified novel glue candidates and validated CMC2 as a DCAF15-recruiting substrate for proof-of-concept degradation, demonstrating a powerful strategy to accelerate glue discovery and guide next-generation targeted protein degradation therapies

Highlighting Clinical Performance of Molecular Glues to Advance Development & Bring Effective Therapies to Patients Faster



Kyle Eastman
Vice President & Head
of Chemistry
Halda Therapeutics
NEW COMPANY

3.00 RIPTACs: Harnessing Cooperative PPIs to Drive Stable Ternary Complexes & Clinical Promise

- Hypothesis driven approach to achieve novel induced proximity pairings with unique mechanism-of-action
- Targeting a cooperative ternary complex to achieve exquisitely selective functional impact in oncology
- Driving translational progress through *in vitro*, *in vivo*, and toxicology studies, to emerging clinical data that highlight RIPTACs' therapeutic promise



Rick Ewing
Vice President & Head
of Chemistry
Rapafusyn Pharmaceuticals

3.30 Chair's Closing Remarks

3.45 End of 4th Molecular Glue Drug Development Summit

Showcase Your Expertise



January 27-29, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Global Platform Designed to Cultivate & Strengthen Strategic Relationships in the Molecular Glue Drug Development Field

With Molecular Glues emerging as the hottest new modality in the induced proximity space, the **4th Molecular Glue Drug Development Summit** offers a unique platform to connect with a technically focused audience of Molecular Glue experts, positioning your services at the forefront of this rapidly expanding field. Join **CXOs, Presidents, VPs** and **Directors** to share your innovative solutions and help accelerate the discovery of molecular glues against novel undruggable targets.

Maximize Your Impact:



Spotlight Your Solutions

Position yourself as the go-to expert for molecular glue developers, engaging leaders eager to discover innovative technologies and services that push the boundaries of the druggable space



Amplify Your Brand Impact


Leverage premium branding and sustained visibility to make your capabilities impossible to overlook, ensuring your solutions leave a lasting mark on this technically focused molecular glue audience



Stay Ahead of the Curve

Gain exclusive insights into emerging research, novel modalities, and evolving market needs, keeping your offerings at the cutting edge of molecular glue drug discovery

Seniority of Attendees



C-level – 16%


President/VP – 13%

Director – 34%

Head/Manager – 17%

Scientists/Academics – 20%

Type of Companies Attending



*Statistics Taken from 3rd Molecular Glue Drug Development Summit

Get Involved



Thomas Walsh

Partnerships Director

+1 617 455 4188

sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book



www.molecular-glue-summit.com/register



+1 617 455 4188



info@hansonwade.com



Supercharge your knowledge of novel molecular glue mechanisms and E3 ligase biology to transform hard-to-drug targets into therapeutic opportunities



Advance your molecular glue programs by leveraging cutting-edge screening assays, library technologies, and discovery platforms to identify, validate, and prioritize the most promising glue candidates



Connect with molecular glue leaders across pharma, biotech, and academia to exchange insights, forge collaborations, and shape the future of molecular glue drug development

Drug Developers*	Early Bird Pricing: Expires Friday, October 31	On the Door Pricing
Conference + 2 Workshops	\$3,297 (save \$900)	\$4,197
Conference + 1 Workshop	\$2,898 (save \$700)	\$3,598
Conference Only	\$2,499 (save \$500)	\$2,999
Academic & Research Institutes**	Early Bird Pricing: Expires Friday, October 31	On the Door Pricing
Conference + 2 Workshops	\$2,697 (save \$900)	\$3,597
Conference + 1 Workshop	\$2,398 (save \$700)	\$3,098
Conference Only	\$2,099 (save \$500)	\$2,599
Solution & Service Providers	Early Bird Pricing: Expires Friday, October 31	On the Door Pricing
Conference + 2 Workshops	\$4,197 (save \$900)	\$5,097
Conference + 1 Workshop	\$3,698 (save \$700)	\$4,398
Conference Only	\$3,199 (save \$500)	\$3,699

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be a full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: info@hansonwade.com



Venue

Hilton Boston Logan Airport

One Hotel Dr, Boston, MA 02128, United States

<https://www.hilton.com/en/hotels/boslhnh-hilton-boston-logan-airport/>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom



+1 617 455 4188

info@hansonwade.com

www.molecular-glue-summit.com



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE